Registro:

Referencias:

• Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer (2012) Immunity, 36, pp. 322-335
• Rabinovich, G.A., Toscano, M.A., Jackson, S.S., Vasta, G.R., Functions of cell surface galectin-glycoprotein lattices (2007) Curr Opin Struct Biol, 17, pp. 513-520
• Liu, F.T., Rabinovich, G.A., Galectins: Regulators of acute and chronic inflammation (2010) Ann N y Acad Sci, 1183, pp. 158-182
• Hirabayashi, J., Hashidate, T., Arata, Y., Oligosaccharide specificity of galectins: A search by frontal affinity chromatography (2002) Biochim Biophys Acta, 1572, pp. 232-254
• Rabinovich, G.A., Vidal, M., Galectins and microenvironmental niches during hematopoiesis (2011) Curr Opin Hematol, 18, pp. 443-451
• Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Differential glycosylation of Th1, Th2 and Th-17 effector cells selectively regulates susceptibility to cell death (2007) Nat Immunol, 8, pp. 825-834
• Ilarregui, J.M., Croci, D.O., Bianco, G.A., Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin (2009) Nat Immunol, 10, pp. 981-991
• Starossom, S.C., Mascanfroni, I.D., Imitola, J., Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration (2012) Immunity, 37, pp. 249-263
• Dalotto-Moreno, T., Croci, D.O., Cerliani, J.P., Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease (2013) Cancer Res, 73, pp. 1107-1117
• Cedeno-Laurent, F., Watanabe, R., Teague, J.E., Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma (2012) Blood, 119, pp. 3534-3538. , This study shows that galectin-1 from CTCL cells interferes with the antitumor T-cell responses and leads to Th2 cytokine bias, characteristic of this lymphoma type
• Zhu, C., Anderson, A.C., Schubart, A., The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity (2005) Nat Immunol, 6, pp. 1245-1252
• Anderson, D.E., TIM-3 as a therapeutic target in human inflammatory diseases (2007) Expert Opin Ther Targets, 11, pp. 1005-1009
• Ito, K., Stannard, K., Gabutero, E., Galectin-1 as a potent target for cancer therapy: Role in the tumor microenvironment (2012) Cancer Metastasis Rev, 31, pp. 763-778
• Rubinstein, N., Alvarez, M., Zwirner, N.W., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege (2004) Cancer Cell, 5, pp. 241-251
• Juszczynski, P., Ouyang, J., Monti, S., The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma (2007) Proc Natl Acad Sci USA, 104, pp. 13134-13139
• Banh, A., Zhang, J., Cao, H., Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis (2011) Cancer Res, 71, pp. 4423-4431
• Demotte, N., Stroobant, V., Courtoy, P.J., Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes (2008) Immunity, 28, pp. 414-424
• Tsuboi, S., Sutoh, M., Hatakeyama, S., A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans (2011) EMBO J, 30, pp. 3173-3185
• Thijssen, V.L., Barkan, B., Shoji, H., Tumor cells secrete galectin-1 to enhance endothelial cell activity (2010) Cancer Res, 70, pp. 6216-6224
• Croci, D.O., Salatino, M., Rubinstein, N., Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma (2012) J Exp Med, 209, pp. 1985-2000
• Laderach, D.J., Gentilini, L.D., Giribaldi, L., A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease (2013) Cancer Res, 73, pp. 86-96
• Markowska, A.I., Jefferies, K.C., Panjwani, N., Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells (2011) J Biol Chem, 286, pp. 29913-29921
• Nangia-Makker, P., Balan, V., Raz, A., Regulation of tumor progression by extracellular galectin-3 (2008) Cancer Microenviron, 1, pp. 43-51
• Delgado, V.M., Nugnes, L.G., Colombo, L.L., Modulation of endothelial cell migration and angiogenesis: A novel function for the ẫtandem-repeat' lectin galectin-8 (2011) FASEB J, 25, pp. 242-254
• Mathieu, V., De Lassalle, E.M., Toelen, J., Galectin-1 in melanoma biology and related neo-angiogenesis processes (2012) J Invest Dermatol, 132, pp. 2245-2254
• Harris, N.L., Jaffe, E.S., Diebold, J., Classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia (1997) J Clin Oncol, 17, pp. 3835-3849. , World Health Organization November
• Tripodo, C., Sangaletti, S., Piccaluga, P.P., The bone marrow stroma in hematological neoplasms - A guilty bystander (2011) Nat Rev Clin Oncol, 8, pp. 456-466
• De Jong, D., Fest, T., The microenvironment in follicular lymphoma (2011) Best Pract Res Clin Haematol, 24, pp. 135-146
• Re, D., Thomas, R.K., Behringer, K., Diehl, V., From Hodgkin disease to Hodgkin lymphoma: Biologic insights and therapeutic potential (2005) Blood, 105, pp. 4553-4560
• Kanzler, H., Hansmann, M.L., Kapp, U., Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin's lymphoma patient (1996) Blood, 7, pp. 3429-3436
• Re, D., Kuppers, R., Diehl, V., Molecular pathogenesis of Hodgkin's lymphoma (2005) J Clin Oncol, 23, pp. 6379-6386
• Gandhi, M.K., Moll, G., Smith, C., Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma (2007) Blood, 110, pp. 1326-1329
• Rodig, S.J., Ouyang, J., Juszczynski, P., AP1-dependent galectin-1 expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features (2008) Clin Cancer Res, 14, pp. 3338-3344
• Suzuki, O., Hirsch, B., Abe, M., Galectin-1-mediated cell death is increased by CD30-induced signaling in anaplastic large cell lymphoma cells but not in Hodgkin lymphoma cells (2012) Lab Invest, 92, pp. 191-199
• Zacaŕas Fluck, M.F., Hess, L., Salatino, M., The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide (2012) Cancer Immunol Immunother, 61, pp. 469-480
• Kamper, P., Ludvigsen, M., Bendix, K., Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma (2011) Blood, 117, pp. 6638-6649
• Ouyang, J., Plutschow, A., Pogge Von Strandmann, E., Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma (2013) Blood, 121, pp. 3431-3433. , This study highlights the association of galectin-1 serum levels with tumor burden and clinical features in a large cohort of newly diagnosed cHL patients
• Heslop, H.E., How i treat EBV lymphoproliferation (2009) Blood, 114, pp. 4002-4008
• Ouyang, J., Juszczynski, P., Rodig, S.J., Viral induction and targeted inhibition of galectin-1 in EBVÃ posttransplant lymphoproliferative disorders (2011) Blood, 117, pp. 4315-4322. , This study shows that EBV antigens promote galectin-1 expression in transformed B cells and highlights the potential utility of neutralizing galectin-1 as a therapeutic strategy for EBVÃ posttransplant lymphoproliferative disorders
• Conconi, A., Ponzio, C., Lobetti-Bodoni, C., Incidence, risk factors and outcome of histological transformation in follicular lymphoma (2012) Br J Haematol, 157, pp. 188-196
• Shipp, M.A., Ross, K.N., Tamayo, P., Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning (2002) Nat Med, 8, pp. 68-74
• Hoyer, K.K., Pang, M., Gui, D., An antiapoptotic role for galectin-3 in diffuse large B-cell lymphomas (2004) Am J Pathol, 164, pp. 893-902
• Clark, M.C., Pang, M., Hsu, D.K., Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death (2012) Blood, 120, pp. 4635-4644. , This report identifies the phosphatase CD45 as the main counterreceptor for galectin-3 on DLBCL cells and presents evidence of the potential therapeutic use of galectin-3-specific inhibitors in this disease
• Demers, M., Biron-Pain, K., Hebert, J., Galectin-7 in lymphoma: Elevated expression in human lymphoid malignancies and decreased lymphoma dissemination by antisense strategies in experimental model (2007) Cancer Res, 67, pp. 2824-2829
• Chiorazzi, N., Rai, K.R., Ferrarini, M., Chronic lymphocytic leukemia (2005) N Engl J Med, 352, pp. 804-815
• Croci, D.O., Morande, P.E., Dergan-Dylon, S., Nurse-like cells control the activity of chronic lymphocytic leukemia B cells via galectin-1 (2012) Leukemia, , 10.1038/leu.2012.315. [Epub ahead of print]. This article highlights the role of galectin-1 expressed by nurse-like cells as a prosurvival and activating signal for CLL cells
• Gardner, J.M., Evans, K.G., Musiek, A., Update on treatment of cutaneous T-cell lymphoma (2009) Curr Opin Oncol, 21, pp. 131-137
• Papadavid, E., Economidou, J., Psarra, A., The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome (2003) Br J Dermatol, 148, pp. 709-718
• Roberts, A.A., Amano, M., Felten, C., Galectin-1-mediated apoptosis in mycosis fungoides: The roles of CD7 and cell surface glycosylation (2003) Mod Pathol, 16, pp. 543-551
• Jabbour, E., Kantarjian, H., Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management (2012) Am J Hematol, 87, pp. 1037-1045
• Yamamoto-Sugitani, M., Kuroda, J., Ashihara, E., Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia (2011) Proc Natl Acad Sci USA, 108, pp. 17468-17473. , The first description of galectin-3 as a prosurvival factor for CML
• O'donnell, M.R., Appelbaum, F.R., Coutre, S.E., Acute myeloid leukemia (2008) J Natl Compr Canc Netw, 6, pp. 962-993
• Cheng, C.L., Hou, H.A., Lee, M.C., Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia (2013) Blood, 121, pp. 3172-3180. , This study identifies galectin-3 as an independent poor prognostic factor and as a new biomarker in AML
• Ustun, C., Miller, J.S., Munn, D.H., (2011) Regulatory T Cells in Acute Myelogenous Leukemia: Is It Time for Immunomodulation? Blood, 118, pp. 5084-5095
• Zhou, Q., Munger, M.E., Veenstra, R.G., Coexpression of Tim-3 and PD-1 identifies a CD8Ã T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia (2011) Blood, 117, pp. 4501-4510
• Palumbo, A., Anderson, K., Multiple myeloma (2011) N Engl J Med, 364, pp. 1046-1060
• Streetly, M.J., Maharaj, L., Joel, S., GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death (2010) Blood, 115, pp. 3939-3948
• Mirandola, L., Yu, Y., Chui, K., Galectin-3C inhibits tumor growth and increases the anticancer activity of bortezomib in a murine model of human multiple myeloma (2011) PLoS ONE, 6, pp. e21811
• Abroun, S., Otsuyama, K., Shamsasenjan, K., Galectin-1 supports the survival of CD45RA(-) primary myeloma cells in vitro (2008) Br J Haematol, 142, pp. 754-765
• Kobayashi, T., Kuroda, J., Ashihara, E., Galectin-9 exhibits antimyeloma activity through JNK and p38 MAP kinase pathways (2010) Leukemia, 24, pp. 843-850

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------